Golimumab for Rheumatoid Arthritis.

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) treatment has evolved with new genetically-engineered molecules beyond infliximab.
• Golimumab (GLM) represents a significant advancement in biologic therapies for RA.

Purpose of the Study:

• To review current data on golimumab (GLM) for rheumatoid arthritis (RA) treatment.
• To evaluate the safety, efficacy, tolerability, and immunogenicity of GLM.

Main Methods:

• Analysis of Phase III clinical trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-MORE, GO-FURTHER, GO-NICE).
• Inclusion of real-world data studies.
• Comparative assessment against other tumor necrosis factor-α (TNF-α) inhibitors.

Main Results:

• Subcutaneous GLM shows efficacy and a favorable safety profile at standard doses.
• A 100 mg subcutaneous dose is linked to increased risks of opportunistic infections, lymphoma, and demyelination.
• GLM is non-inferior to other TNF-α agents, with potential advantages in immunogenicity and drug persistence.

Conclusions:

• Golimumab (GLM) is a well-tolerated and effective treatment option for rheumatoid arthritis (RA).
• GLM offers a convenient dosage scheme for both clinicians and patients.
• Risk stratification is necessary for higher subcutaneous GLM doses.